Nav: Home

A glow stick that detects cancer?

May 01, 2017

Chemiluminescence, or chemical light, is the principle behind the glow sticks (also known as light sticks) used at rock concerts and as quick tools to grab when the electricity goes out. But they can also be used to diagnose diseases by identifying concentrations of biological samples. A new mechanism developed by Tel Aviv University researchers produces a 3,000-times-brighter, water-resistant chemiluminescent probe with particular application to medical and cancer diagnosis.

The research found that tweaking the electronic structure of current probes improves their inherent fluorescence. This could lead to the invention of a new single-component system with multiple applications -- including the detection and measurement of cellular activity that points to certain pathologies, such as cancer. The study was recently published in ACS Central Science.

"Chemiluminescence is considered one of the most sensitive methods used in diagnostic testing," said Prof. Doron Shabat of TAU's School of Chemistry, who led the research. "We have developed a method to prepare highly efficient compounds that emit light upon contact with a specific protein or chemical. These compounds can be used as molecular probes to detect cancerous cells, among other applications."

Fixing a glitch

The research, conducted in collaboration with Dr. Christoph Bauer of Geneva University, repairs an energy-loss "glitch" in current chemiluminescent probes. Most systems use a mixture of one emitter molecule that detects the species of interest, and another two additional ingredients -- a fluorophore and a soap-like substance called a surfactant -- that amplify the signal to detectable levels. But energy is lost in the transfer process from the emitter molecule to the fluorophore, and surfactants are not biocompatible.

"As synthetic chemists, we knew how to link structure and function," said Prof. Shabat. "By adding two key atoms, we created a much brighter probe than those currently on the market. In addition, this particular molecule is suitable for direct use in cells."

Based on this molecule, the researchers developed sensors to detect several biologically relevant chemicals. They also used the chemiluminescent molecule to measure the activity of several enzymes and to image cells by microscopy.

"This gives us a new powerful methodology with which we can prepare highly efficient chemiluminescence sensors for the detection, imaging and analysis of various cell activities," said Prof. Shabat. The researchers are currently exploring ways of amplifying the chemiluminescence of the new probes for in vivo imaging.
-end-
The research was funded in part by the Israel Science Foundation, the Binational Science Foundation, the German Israeli Foundation, and the Israeli National Nanotechnology Initiative.

American Friends of Tel Aviv University (AFTAU) supports Israel's most influential, comprehensive and sought-after center of higher learning, Tel Aviv University (TAU). TAU is recognized and celebrated internationally for creating an innovative, entrepreneurial culture on campus that generates inventions, startups and economic development in Israel. For three years in a row, TAU ranked 9th in the world, and first in Israel, for alumni going on to become successful entrepreneurs backed by significant venture capital, a ranking that surpassed several Ivy League universities. To date, 2,400 patents have been filed out of the University, making TAU 29th in the world for patents among academic institutions.

American Friends of Tel Aviv University

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Uncharted
There's so much we've yet to explore–from outer space to the deep ocean to our own brains. This hour, Manoush goes on a journey through those uncharted places, led by TED Science Curator David Biello.
Now Playing: Science for the People

#555 Coronavirus
It's everywhere, and it felt disingenuous for us here at Science for the People to avoid it, so here is our episode on Coronavirus. It's ok to give this one a skip if this isn't what you want to listen to right now. Check out the links below for other great podcasts mentioned in the intro. Host Rachelle Saunders gets us up to date on what the Coronavirus is, how it spreads, and what we know and don't know with Dr Jason Kindrachuk, Assistant Professor in the Department of Medical Microbiology and infectious diseases at the University of Manitoba. And...
Now Playing: Radiolab

Dispatch 1: Numbers
In a recent Radiolab group huddle, with coronavirus unraveling around us, the team found themselves grappling with all the numbers connected to COVID-19. Our new found 6 foot bubbles of personal space. Three percent mortality rate (or 1, or 2, or 4). 7,000 cases (now, much much more). So in the wake of that meeting, we reflect on the onslaught of numbers - what they reveal, and what they hide.  Support Radiolab today at Radiolab.org/donate.